- Home
- CCCC vs NVX Comparison
CCCC vs NVX Comparison
Compare CCCC & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- NVX
- Stock Information
- Founded
- CCCC 2015
- NVX 2012
- Country
- CCCC United States
- NVX Australia
- Employees
- CCCC N/A
- NVX N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- NVX Industrial Machinery/Components
- Sector
- CCCC Health Care
- NVX Miscellaneous
- Exchange
- CCCC Nasdaq
- NVX Nasdaq
- Market Cap
- CCCC 175.1M
- NVX 210.3M
- IPO Year
- CCCC 2020
- NVX N/A
- Fundamental
- Price
- CCCC $2.71
- NVX $1.26
- Analyst Decision
- CCCC Buy
- NVX
- Analyst Count
- CCCC 3
- NVX 0
- Target Price
- CCCC $8.00
- NVX N/A
- AVG Volume (30 Days)
- CCCC 1.2M
- NVX 156.6K
- Earning Date
- CCCC 10-30-2025
- NVX 01-01-0001
- Dividend Yield
- CCCC N/A
- NVX N/A
- EPS Growth
- CCCC N/A
- NVX N/A
- EPS
- CCCC N/A
- NVX N/A
- Revenue
- CCCC $34,240,000.00
- NVX $5,931,433.00
- Revenue This Year
- CCCC N/A
- NVX $135.22
- Revenue Next Year
- CCCC N/A
- NVX $1,647.66
- P/E Ratio
- CCCC N/A
- NVX N/A
- Revenue Growth
- CCCC 16.55
- NVX N/A
- 52 Week Low
- CCCC $1.09
- NVX $0.81
- 52 Week High
- CCCC $7.22
- NVX $2.73
- Technical
- Relative Strength Index (RSI)
- CCCC 60.68
- NVX 45.57
- Support Level
- CCCC $2.57
- NVX $1.25
- Resistance Level
- CCCC $2.85
- NVX $1.35
- Average True Range (ATR)
- CCCC 0.19
- NVX 0.08
- MACD
- CCCC -0.01
- NVX -0.01
- Stochastic Oscillator
- CCCC 72.88
- NVX 32.31
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.